Chong Kun Dang Pharmaceutical - Asset Resilience Ratio
Chong Kun Dang Pharmaceutical (185750) has an Asset Resilience Ratio of 6.04% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Chong Kun Dang Pharmaceutical PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Chong Kun Dang Pharmaceutical's Asset Resilience Ratio has changed over time. See how leveraged is Chong Kun Dang Pharmaceutical's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Chong Kun Dang Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Chong Kun Dang Pharmaceutical market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩110.67 Billion | 6.04% |
| Total Liquid Assets | ₩110.67 Billion | 6.04% |
Asset Resilience Insights
- Limited Liquidity: Chong Kun Dang Pharmaceutical maintains only 6.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Chong Kun Dang Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Chong Kun Dang Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Chong Kun Dang Pharmaceutical (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Chong Kun Dang Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.24% | ₩130.27 Billion ≈ $88.28 Million |
₩1.80 Trillion ≈ $1.22 Billion |
+2.18pp |
| 2024-12-31 | 5.05% | ₩73.70 Billion ≈ $49.95 Million |
₩1.46 Trillion ≈ $988.58 Million |
-5.32pp |
| 2023-12-31 | 10.37% | ₩145.42 Billion ≈ $98.55 Million |
₩1.40 Trillion ≈ $950.41 Million |
+6.95pp |
| 2022-12-31 | 3.42% | ₩38.44 Billion ≈ $26.05 Million |
₩1.12 Trillion ≈ $762.32 Million |
-1.89pp |
| 2021-12-31 | 5.30% | ₩55.52 Billion ≈ $37.63 Million |
₩1.05 Trillion ≈ $709.33 Million |
+1.27pp |
| 2020-12-31 | 4.04% | ₩38.20 Billion ≈ $25.89 Million |
₩946.33 Billion ≈ $641.32 Million |
+2.11pp |
| 2019-12-31 | 1.93% | ₩15.45 Billion ≈ $10.47 Million |
₩801.35 Billion ≈ $543.06 Million |
-- |
About Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in… Read more